- Home
- RMCF vs TPST Comparison
RMCF vs TPST Comparison
Compare RMCF & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | TPST |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 30.9M |
| IPO Year | 2024 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RMCF | TPST |
|---|---|---|
| Price | $2.59 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 36.7K | ★ 278.7K |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $1.50 |
| 52 Week High | $2.99 | $12.22 |
Technical Indicators
Market Signals| Indicator | RMCF | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 52.45 |
| Support Level | $2.03 | $1.57 |
| Resistance Level | $2.53 | $2.48 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 49.63 | 67.59 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.